Global Blood Therapeutics, Inc.
GBTDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001629137
Global Blood Therapeutics, Inc. was delisted in 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.75B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Global Blood Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Global Blood Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Patrick Deval L | Director | 0 | Oct 6, 2022 | 0 |
| Yarno Wendy L | Director | 0 | Oct 6, 2022 | 0 |
| Love Ted W | President and CEO | 0Indirect | Oct 6, 2022 | 0 |
| Perry Mark L | Director | 0 | Oct 6, 2022 | 0 |
| Suvari Tricia Borga | Chief Legal Officer | 0 | Oct 6, 2022 | 0 |
| Pierce Glenn | Director | 0 | Oct 6, 2022 | 0 |
| Farrow Jeffrey S | Chief Financial Officer | 0 | Oct 6, 2022 | 0 |
| Pizzo Philip A. | Director | 0 | Oct 6, 2022 | 0 |
| Svoronos Dawn | Director | 0 | Oct 6, 2022 | 0 |
| Choi Jung | See Remarks | 0Indirect | Oct 6, 2022 | 0 |
| Morrison Scott W | Director | 0 | Oct 6, 2022 | 0 |
| Johnson David Lee | Chief Commercial Officer | 0 | Oct 6, 2022 | 0 |
| Krehlik Carrie | Chief Human Resources Officer | 0 | Oct 6, 2022 | 0 |
| Thompson Alexis A. | Director | 0 | Oct 6, 2022 | 0 |
| Smith-Whitley Kim | See Remarks | 0 | Oct 6, 2022 | 0 |
| Habibizad Nazila | See Remarks | 0 | Oct 6, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | Farrow Jeffrey SChief Financial Officer | SSale | −31.4K | $68.00 | −$2.14M | −91.1%3.09K after | |
| Aug 19, 2022 (view filing) | Aug 18 | 1 day | Habibizad NazilaSee Remarks | SSale | −4.68K | $67.19 | −$314.3K | −34.4%8.92K after | |
| Jun 22, 2022 (view filing) | Jun 21 | 1 day | Pizzo Philip A.Director | SSale | −1.26K | $27.25 | −$34.3K | −12.1%9.11K after | |
| Jun 22, 2022 (view filing) | Jun 21 | 1 day | Svoronos DawnDirector | SSale | −1.91K | $27.24 | −$52.0K | −26.2%5.38K after | |
| Sep 10, 2021 (view filing) | Sep 9 | 1 day | Morrison Scott WDirector | SSale | −4.80K | $30.21 | −$145.0K | −61.2%3.04K after |